The disease burden of invasive meningococcal serogroup B disease in Canada

Pediatric Infectious Disease Journal

Volumn 32, Issue 1, 2013, Pages

  Bettinger, Julie A ^a   Scheifele, David W ^a   Le Saux, Nicole ^b   Halperin, Scott A ^c   Vaudry, Wendy ^d   Tsang, Raymond ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

meningitis; meningococcal; serogroup B; surveillance

Indexed keywords

ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; FATALITY; HEALTH SURVEY; HOSPITAL ADMISSION; HUMAN; IMMUNIZATION; INCIDENCE; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVOR;

ADULT; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MORBIDITY; NEISSERIA MENINGITIDIS;

EID: 84871743318     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182706b89     Document Type: Article

References (19)

1. Bettinger JA, Scheifele DW, Le Saux N, et al. Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J. 2009;28:220-224.
2. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840-847.
3. Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine. 2009;27:1735-1740.
4. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71-e79.
5. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127-1137.
6. Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28:5023-5030.
7. Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18:483-486.
8. Scheifele DW. IMPACT after 17 years: lessons learned about successful networking. Paediatr Child Health. 2009;14:33-35.
9. Le Saux N, Bettinger JA, Wootton S, et al. Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. Can J Infect Dis Med Microbiol. 2009;20:e130-e134.
10. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA. 1998;95:3140-3145. (Pubitemid 28135868)
11. Spanjaard L, Bol P, de Marie S, et al. Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83. Bull World Health Organ. 1987;65:861-868. (Pubitemid 18067165)
12. Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. 2006;118:e979-e984. (Pubitemid 46393746)
13. Law DK, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol. 2006;44:2743-2749. (Pubitemid 44228566)
14. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26:1159-1164. (Pubitemid 28215481)
15. Gottfredsson M, Reynisson IK, Ingvarsson RF, et al. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis. 2011;53:e117-e124.
16. An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep. 2001;27:2-36.
17. Whalen CM, Hockin JC, Ryan A, et al. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA. 1995;273:390-394.
18. Howitz M, Lambertsen L, Simonsen JB, et al. Morbidity, mortality and spatial distribution of meningococcal disease, 1974-2007. Epidemiol Infect. 2009;137:1631-1640.
19. Diggle MA, Bell CM, Clarke SC. Nucleotide sequence-based typing of meningococci directly from clinical samples. J Med Microbiol. 2003;52(pt 6):505-508. (Pubitemid 36774238)